Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status von Desai, Neil P, Trieu, Vuong, Hwang, Larn Yuan, Wu, Rujin, Soon-Shiong, Patrick, Gradishar, William J

Volltext

Identification of a RING protein that can interact in vivo with the BRCA1 gene product von Wu, Leeju C, Wang, Zhuo Wei, Tsan, Julia Tsou, Spillman, Monique A, Phung, Anne, Xu, Xie L, Yang, Meng-Chun W, Hwang, Larn-Yuan, Bowcock, Anne M, Baer, Richard

Volltext

Abstract 3968: OT-101/Chemotherapy - A novel mechanism of action (MOA) in pancreatic cancer immunization therapy von Nam, David, Hwang, Larn, Trieu, Vuong

Volltext

Breaking immune tolerance for the treatment of pancreatic cancer: Phase I/II clinical experience von Nam, David, Hwang, Larn, Trieu, Vuong N.

Volltext

Breaking immune tolerance for the treatment of glioblastoma: Phase IIb clinical trial experience von Hwang, Larn, Nam, David, Trieu, Vuong N.

Volltext

Abstract 5029: OT-101/Chemotherapy- A novel mechanism of action (MOA) in glioblastoma immunization therapy von Hwang, Larn, Nam, David, Uckun, Fatih, Trieu, Vuong

Volltext

ATIM-10. CLINICAL PREDICTORS OF RESPONSE FOR RECURRENT/REFRACTORY GLIOBLASTOMA MULTIFORME (GBM) AND ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE III) PATIENTS TREATED WITH THE ANTI-TGFß2... von Qazi, Sanjive, Nam, David, Hwang, Larn, Trieu, Vuong, Uckun, Fatih

Volltext

ATIM-03. ANTI-TGFß2 RNA THERAPEUTIC OT-101 INDUCES DURABLE OBJECTIVE RESPONSES IN PATIENTS WITH RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA MULTIFORME (GBM, WHO GRADE 4) OR ANAPLASTIC... von Uckun, Fatih, Qazi, Sanjive, Hwang, Larn, Nam, David, Trieu, Vuong

Volltext

ATIM-06. TREATMENT OF RECURRENT/REFRACTORY (R/R) ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE 3) PATIENTS WITH ANTI-TGFß2 RNA THERAPEUTIC OT-101 VERSUS TEMOZOLOMIDE IS ASSOCIATED WITH IMP... von Uckun, Fatih, Qazi, Sanjive, Nam, David, Hwang, Larn, Trieu, Vuong

Volltext

Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up von Uckun, Fatih M., Qazi, Sanjive, Hwang, Larn, Trieu, Vuong N.

Volltext

Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ 2 -Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up von Uckun, Fatih M, Qazi, Sanjive, Hwang, Larn, Trieu, Vuong N

Volltext

Abstract 2800: Transforming growth factor-beta 2 (TGF-β2) antisense oligonucleotide (ASO) OT-101 synergizes with chemotherapy in preclinical tumor models von D'Cruz, Osmond, Lee, Cynthia, Trieu, Vuong, Hwang, Larn

Volltext

Abstract 5043: Population pharmacokinetic model for OT-101 - A TGF-β2-specific antisense oligonucleotide in cancer patients von Wang, Wen, Ng, Kevin, Nam, David, Trieu, Vuong, Hwang, Larn

Volltext

A Direct Interaction Between EXT Proteins and Glycosyltransferases is Defective in Hereditary Multiple Exostoses von Simmons, Andrew D., Musy, Maurice M., Lopes, Carla S., Hwang, Larn-Yuan, Yang, Ya-Ping, Lovett, Michael

Volltext

Abstract 3742: Treatment with trabedersen, an anti-TGF-beta 2 antisense, primed tumors to subsequent chemotherapies von Hwang, Larn, Ng, Kevin, Wang, Wen, Trieu, Vuong

Volltext

OT-101: An anti-TGF-beta-2 antisense- primed tumors to subsequent chemotherapies von Hwang, Larn, Ng, Kevin, Wang, Wen, Trieu, Vuong N.

Volltext

Abstract B67: IG-001: A non-biologic nanoparticle paclitaxel for the treatment of ovarian cancer von Hwang, Larn, Cheng, Catherine, Trieu, Vuong

Volltext

Abstract 1600: Interleukin-8 (IL-8) in TGF-β immunotherapy and chemotherapies von Hwang, Larn, Ng, Kevin, D’Cruz, Osmond, Qazi, Sanjive, Schmidt, Andrew, Trieu, Vuong

Volltext

IL-8 as PD biomarker for TGF-b antisense (OT-101) therapy: Results of a phase II trial von Trieu, Vuong N., Wang, Wen, Qazi, Sanjive, Ng, Kevin, D'Cruz, Osmond, Nam, David, Hwang, Larn

Volltext

Correlation of circulating IL-8 levels with improved overall survival in advanced pancreatic cancer patients in response to antisense OT-101 (trabedersen) therapy von Trieu, Vuong N., D'Cruz, Osmond, Qazi, Sanjive, Ng, Kevin, Hwang, Larn

Volltext